System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Elena Castro is an expert in Oncology at Hospital Universitario 12 De Octubre (Spain). As of October 2026, ScienceLeadR ranks Elena Castro in the top 1% of experts worldwide for Prostatic Diseases, Urogenital Neoplasms and Genital Diseases, Male. Elena Castro has authored 224 publications, the most recent in 2026, and is an investigator in 18 clinical trials, 8 of them ongoing. SLR score: 1,241 (community average: 125). How the SLR is computed.

LeadR Profile

Elena Castro Hospital Universitario 12 De Octubre Spain
1 241 ScienceLeadR Reputation 1241

Unlock

Register Login
Network Map

Oncology

Subspecialties: Urology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2012 - 2026
Source: PubMed

Hospital Universitario 12 De Octubre

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 224

Citations

Citations: 8 303 1st author: 37 Last author: 23 Unique author: 3

Main journals

J Clin Oncol 45
Eur Urol 21
Ann Oncol 18
Br J Cancer 9
Cancers (Basel) 8

Best Journals

J Clin Oncol 35
Ann Oncol 16
Lancet Oncol 4

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Management of Patients with High-risk Localised, Locally Advanced, and Biochemically Recurrent Prostate Cancer: Report from the 2026 Advanced Prostate Cancer Consensus Conference.
PMID 42934071 — urology, neoplasms, prostate, prostatic neoplasms		Eur Urol20260
Talazoparib plus enzalutamide in high-volume metastatic hormone-naive prostate cancer: a randomized phase 2 trial.
PMID 42875559 — genes, recombination, genetic, poly(adp-ribose) polymerases, homologous recombination, androgens, neoplasms, prostate, poly adenosine diphosphate ribose, hormones, recombinational dna repair, prostatic neoplasms, therapeutics		Nat Med Top journal20260
Real-world treatment patterns in men with metastatic hormone-sensitive prostate cancer in Europe and Asia between 2020 and 2024.
PMID 42757692 — docetaxel, androgens, neoplasms, prostate, hormones, prostatic neoplasms, therapeutics		Oncologist20260
Treatment patterns and clinical outcomes among patients with metastatic castration-resistant prostate cancer: a multinational retrospective medical record review.
PMID 42735580 — neoplasms, prostate, hormones, prostatic neoplasms, diagnosis, castration, records, therapeutics, medical records		Cancer Treat Res Commun20260
A spotlight on PTEN alterations in prostate cancer: a narrative review.
PMID 42497972 — neoplasms, prostate, prostatic neoplasms, therapeutics		Crit Rev Oncol Hematol20260

Clinical Studies 18

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

Phase 2 6
N/A 5
Phase 3 5
Phase 1/Phase 2 2

By status:

Recruiting 7
Active not recruiting 5
Completed 4
Unknown 2

By type:

Interventional 14
Observational 4

By Monocentric/Multicentric:

monocentric 2
multicentric2to4 0
multicentric5to9 2
multicentricup10 14

Main Topics

Cohort/Consortium Investigators 8

Ongoing Clinical Trials

8 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A clinical trial to learn about the effects of AMO959 given with AAA617 and an androgen receptor pathway inhibitor (ARPI) in adults with PSMA positive prostate cancer that has spread to other parts of the body pathway inhibitor (ARPI) in adults with PSMA positive prostate cancer that has spread to other parts of the body
2025-521859-23-00 — protein kinases, androgens, receptors, androgen, neoplasms, multiple chronic conditions, prostate, protein kinase inhibitors, prostatic neoplasms, castration, dna		Phase 1/Phase 2Recruiting2026
Pasritamig vs Placebo in late line Metastatic Castration resistant Prostate Cancer (mCRPC)
2025-520927-26-00 — cells, kallikreins, neoplasms, prostate, prostatic neoplasms, castration, t-lymphocytes		Phase 3Recruiting2025
AZD5305 vs Placebo in Men with Metastatic Castration Sensitive Prostate Cancer Receiving Physician s Choice New Hormonal Agents
2023-504214-30-00 — neoplasms, prostate, prostatic neoplasms, castration, men		Phase 3Active not recruiting2024
Talazoparib plus Enzalutamide after progression to prior ARPi in Metastatic Prostate Cancer
2023-510536-37-00 — androgens, receptors, androgen, neoplasms, prostate, prostatic neoplasms, castration, therapeutics		Phase 2Recruiting2024
Pasritamig With Docetaxel vs Docetaxel in Metastatic Castration resistant Prostate Cancer (mCRPC)
2025-522713-29-00 — cells, kallikreins, docetaxel, neoplasms, prostate, prostatic neoplasms, castration, t-lymphocytes		Phase 3Recruiting2026

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS